Lamotrigine attenuates deficits in synaptic plasticity and accumulation of amyloid plaques in APP/PS1 transgenic mice

[1]  R. Masoudi,et al.  Increased pro–nerve growth factor and decreased brain-derived neurotrophic factor in non–Alzheimer's disease tauopathies , 2014, Neurobiology of Aging.

[2]  M. Tuszynski,et al.  Early BDNF Treatment Ameliorates Cell Loss in the Entorhinal Cortex of APP Transgenic Mice , 2013, The Journal of Neuroscience.

[3]  Heidi E Kirsch,et al.  Seizures and epileptiform activity in the early stages of Alzheimer disease. , 2013, JAMA neurology.

[4]  A. Farmer,et al.  Allele‐specific expression of the serotonin transporter and its transcription factors following lamotrigine treatment in vitro , 2013, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[5]  Michael S. McGrath,et al.  Systemic immune system alterations in early stages of Alzheimer's disease , 2013, Journal of Neuroimmunology.

[6]  Keith A. Vossel,et al.  Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model , 2012, Proceedings of the National Academy of Sciences.

[7]  Amy L. Shelton,et al.  Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment , 2012, Neuron.

[8]  Edward O. Mann,et al.  Inhibitory Interneuron Deficit Links Altered Network Activity and Cognitive Dysfunction in Alzheimer Model , 2012, Cell.

[9]  R. D'Hooge,et al.  TUDCA, a Bile Acid, Attenuates Amyloid Precursor Protein Processing and Amyloid-β Deposition in APP/PS1 Mice , 2012, Molecular Neurobiology.

[10]  A. Svoronos,et al.  The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy , 2011, Epilepsia.

[11]  D. Bredesen,et al.  Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain , 2011, Neurobiology of Aging.

[12]  S. Rothman,et al.  A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam. , 2011, Journal of neurophysiology.

[13]  H. Tanila,et al.  Spontaneous epileptiform discharges in a mouse model of Alzheimer's disease are suppressed by antiepileptic drugs that block sodium channels , 2011, Epilepsy Research.

[14]  Nanxin Li,et al.  The mood stabilizer lamotrigine produces antidepressant behavioral effects in rats: role of brain-derived neurotrophic factor , 2010, Journal of psychopharmacology.

[15]  Julie A. Harris,et al.  Transsynaptic Progression of Amyloid-β-Induced Neuronal Dysfunction within the Entorhinal-Hippocampal Network , 2010, Neuron.

[16]  M. Heneka,et al.  Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits , 2010, Neurochemistry International.

[17]  O. Arancio,et al.  Reversal of long-term dendritic spine alterations in Alzheimer disease models , 2009, Proceedings of the National Academy of Sciences.

[18]  L. Mucke,et al.  Epilepsy and cognitive impairments in Alzheimer disease. , 2009, Archives of neurology.

[19]  Sylvain Rheims,et al.  Amyloid β-Induced Neuronal Hyperexcitability Triggers Progressive Epilepsy , 2009, The Journal of Neuroscience.

[20]  D. Geschwind,et al.  Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease , 2009, Nature Medicine.

[21]  M. Block,et al.  Retinoic Acid Attenuates β-Amyloid Deposition and Rescues Memory Deficits in an Alzheimer's Disease Transgenic Mouse Model , 2008, The Journal of Neuroscience.

[22]  M. Ciotti,et al.  NGF and BDNF signaling control amyloidogenic route and Aβ production in hippocampal neurons , 2008, Proceedings of the National Academy of Sciences.

[23]  Haruo Kasai,et al.  Protein Synthesis and Neurotrophin-Dependent Structural Plasticity of Single Dendritic Spines , 2008, Science.

[24]  M. Schachner,et al.  A TAG1-APP signalling pathway through Fe65 negatively modulates neurogenesis , 2008, Nature Cell Biology.

[25]  L. Buée,et al.  Neurotrophic factors in Alzheimer’s disease: role of axonal transport , 2008, Genes, brain, and behavior.

[26]  Anatol C. Kreitzer,et al.  Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease , 2007, Neuron.

[27]  Ho-Won Lee,et al.  Comparison of Cognitive Effects of Lamotrigine and Oxcarbazepine in Epilepsy Patients , 2007, Journal of clinical neurology.

[28]  Brian J. Bacskai,et al.  Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease , 2006, Neurobiology of Disease.

[29]  L. Hirsch,et al.  Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders , 2006, Expert review of neurotherapeutics.

[30]  Florence Pasquier,et al.  Phenotype associated with APP duplication in five families. , 2006, Brain : a journal of neurology.

[31]  Yaakov Stern,et al.  Incidence and Predictors of Seizures in Patients with Alzheimer's Disease , 2006, Epilepsia.

[32]  A. Granholm,et al.  Altered NGF response but not release in the aged septo-hippocampal cholinergic system , 2005, Experimental Neurology.

[33]  E. Mackenzie,et al.  Akt-dependent Expression of NAIP-1 Protects Neurons against Amyloid-β Toxicity* , 2005, Journal of Biological Chemistry.

[34]  H. Steinbusch,et al.  Age-related loss of synaptophysin immunoreactive presynaptic boutons within the hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L transgenic mice. , 2005, The American journal of pathology.

[35]  B. Uthman,et al.  New onset geriatric epilepsy , 2005, Neurology.

[36]  L. Maffei,et al.  Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Mrak,et al.  Glia and their cytokines in progression of neurodegeneration , 2005, Neurobiology of Aging.

[38]  H. Steinbusch,et al.  Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. , 2004, The American journal of pathology.

[39]  R. Malinow,et al.  APP Processing and Synaptic Function , 2003, Neuron.

[40]  L. C. Katz,et al.  BDNF release from single cells elicits local dendritic growth in nearby neurons , 2002, Nature Neuroscience.

[41]  A. Cattaneo,et al.  β-Amyloid Plaques in a Model for Sporadic Alzheimer's Disease Based on Transgenic Anti-Nerve Growth Factor Antibodies , 2002, Molecular and Cellular Neuroscience.

[42]  A. Cattaneo,et al.  Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[43]  Tony Wyss-Coray,et al.  Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.

[44]  Jun-Feng Wang,et al.  Lamotrigine Increases Gene Expression of GABA-A Receptor β3 Subunit in Primary Cultured Rat Hippocampus Cells , 2002, Neuropsychopharmacology.

[45]  J. Macdonald,et al.  Effect of Lamotrigine on the Ca2+-Sensing Cation Current in Cultured Hippocampal Neurons , 2001 .

[46]  N. Berardi,et al.  Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice , 2000 .

[47]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[48]  Nicoletta Berardi,et al.  Phenotypic Knockout of Nerve Growth Factor in Adult Transgenic Mice Reveals Severe Deficits in Basal Forebrain Cholinergic Neurons, Cell Death in the Spleen, and Skeletal Muscle Dystrophy , 2000, The Journal of Neuroscience.

[49]  M. Brodie,et al.  Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy , 1999, Epilepsy Research.

[50]  G. Sperk,et al.  Neuropeptide Y: emerging evidence for a functional role in seizure modulation , 1999, Trends in Neurosciences.

[51]  Jullie W Pan,et al.  Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults , 1999, Neurology.

[52]  B. Sommer,et al.  Neuron loss in APP transgenic mice , 1998, Nature.

[53]  J. Messenheimer,et al.  Safety Review of Adult Clinical Trial Experience with Lamotrigine , 1998, Drug safety.

[54]  B. Lu,et al.  Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus , 1996, Nature.

[55]  H. Thoenen,et al.  Localization of Cellular Storage Compartments and Sites of Constitutive and Activity-Dependent Release of Nerve Growth Factor (NGF) in Primary Cultures of Hippocampal Neurons , 1996, Molecular and Cellular Neuroscience.

[56]  E. Schuman,et al.  Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus , 1995, Science.

[57]  J. Troncoso,et al.  Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease , 1994, The Lancet.

[58]  E. Arenas,et al.  Neurotrophin-3 prevents the death of adult central noradrenergic neurons in vivo , 1994, Nature.

[59]  J. Growdon,et al.  Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[60]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[61]  M. Leach,et al.  Pharmacological Studies on Lamotrigine, A Novel Potential Antiepileptic Drug , 1986, Epilepsia.

[62]  R. Morris.  Developments of a water-maze procedure for studying spatial learning in the rat , 1984, Journal of Neuroscience Methods.

[63]  Ru Zhang,et al.  Novel object recognition as a facile behavior test for evaluating drug effects in AβPP/PS1 Alzheimer's disease mouse model. , 2012, Journal of Alzheimer's disease : JAD.

[64]  L. Maffei,et al.  Environmental enrichment delays the onset of memory deficits and reduces neuropathological hallmarks in a mouse model of Alzheimer-like neurodegeneration. , 2007, Journal of Alzheimer's disease : JAD.

[65]  S. Tekin,et al.  Antiglutamatergic therapy in Alzheimer's disease – effects of lamotrigine , 1998, Journal of Neural Transmission.